Skip to main content

Advertisement

Fig. 3 | BMC Cancer

Fig. 3

From: Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation

Fig. 3

The impact of EGFR amplification, TERT promoter mutations, PTEN deletion and MGMT promoter methylation on overall survival of glioma patients. Kaplan-Meier curves of EGFR amplification in GBM IDH-wildtype (a) and in astrocytoma IDH-wildtype (b). Kaplan-Meier curves of TERT promoter mutations (c) and MGMT promoter methylation in GBM IDH-wildtype (d) and in astrocytoma IDH-wildtype (e). The impact of PTEN deletion in overall survival of GBM IDH-wildtype (f), astrocytomas IDH-wildtype (g) and IDH-mutant (h)

Back to article page